Clinical trials: Chronic Myelomonocytic Leukemia-0

Chronic Myelomonocytic Leukemia-0, Chronic Myelomonocytic Leukemia-1

Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

• Active, not recruiting
• Age: 18 years and older
• Phase 1/2

This phase I/II trial identifies the best dose of seclidemstat when given together with azacitidine in treating patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.

Conditions

Chronic Myelomonocytic Leukemia-0, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndrome

Trial name

NCT04734990

Testing

Azacitidine, Seclidemstat

Where

United States

Volunteers

24 people

Sponsor

M.D. Anderson Cancer Center